Washington, D.C. — The Cure Coalition today responded to the U.S.-China Economic and Security Review Commission’s new report exposing deep risks in America’s medical supply chains and research enterprise. The Commission found that a quarter of generic medicines used by Americans now rely on key ingredients produced in China, with some essential health products sourced exclusively from Chinese manufacturers. The report warns that similar vulnerabilities extend to medical research and biotechnology, where U.S. scientific progress and drug innovation risk being tied to foreign supply chains.
“America’s health and security are at stake when we rely on China for the essential ingredients, scientific supplies, and innovation that drive our medical breakthroughs,” said Cara Kingan, Executive Director for the Cure Coalition. “We cannot afford to put patients, research, or future cures at risk. National security begins in the medicine cabinet, and in the laboratory, when American medicines and discoveries are made in America.”
The Commission’s report highlights China’s rapid expansion into advanced fields like synthetic biology, mRNA technology, and genetic research, making China a gatekeeper for the building blocks of tomorrow’s therapies. Many U.S. universities, biotech firms, and medical research centers are dependent on partnerships or supplies linked to China, while quality concerns persist in foreign manufacturing.
Key points from the Commission’s 2025 report:
- 25% of generic drugs taken by Americans rely on key ingredients from China, with vital products (blood thinners, cancer treatments, antibiotics) at risk of disruption.
- The full extent of U.S. dependence is unclear because FDA lacks authority and data to track ingredient and equipment origin, a vulnerability highlighted in the report.
- Chinese leadership in synthetic biology, mRNA platform technologies, and biomanufacturing means America’s future medical advances could be subject to foreign control and supply shocks.
- U.S. medical research and drug innovation are often reliant on Chinese partners, reagents, and equipment, exposing scientific progress to risk if supply chains are severed.
- The report calls for urgent investment in domestic research infrastructure, biomedical manufacturing, and supply chain transparency to secure American health and innovation.
About Cure Coalition
Cure Coalition advocates for responsible, evidence-based biomedical research that keeps our families safe and keeps trusted U.S. research approaches as the standard. As mothers, healthcare professionals, and concerned citizens, we’re committed to advancing treatments and cures through medicines Americans can count on. Learn more at curecoalition.org.